ECM
JAZZ icon

Everence Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Everence Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$549K Buy
2,277
+311
+16% +$68.1K 0.03% 390
2026
Q1 		$372K Buy
1,966
+536
+37% +$93.7K 0.02% 478
2025
Q4 		$243K Buy
+1,430
New +$219K 0.01% 680
2025
Q2 		– Sell
-2,250
Closed -$279K – 819
2025
Q1 		$279K Hold
2,250
– – 0.02% 596
2024
Q4 		$277K Buy
+2,250
New +$265K 0.02% 615

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Everence Capital Management's JAZZ Position: Q2 2026 in Review

Everence Capital Management increased its Jazz Pharmaceuticals (JAZZ) stake by 16% in Q2 2026, buying an estimated $68.1K and bringing the position to 2,277 shares worth $549K. The position accounts for 0.03% of the portfolio, ranked #390.

Everence Capital Management first reported a position in JAZZ in Q4 2024 and has held it in 5 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Everence Capital Management held 2,277 shares of Jazz Pharmaceuticals worth $549K as of Q2 2026.
  • Everence Capital Management bought 311 Jazz Pharmaceuticals shares in Q2 2026, an estimated $68.1K.
  • Jazz Pharmaceuticals made up 0.03% of Everence Capital Management's portfolio in Q2 2026, its #390 holding.
  • Everence Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.